New drug trial aims to stop dangerous transplant complication

This study is testing whether a drug called ivarmacitinib can prevent acute graft-versus-host disease (aGVHD) in people with blood cancers who receive stem cell transplants from partially matched donors. The trial will enroll 32 patients to see how well the drug prevents moderate to severe aGVHD and monitor safety. Researchers will track whether patients develop this immune complication, infections, and other transplant-related issues over 12 months.